Abbreviated Therapeutic Plasma Exchange with Caplacizumab Maintains Platelet Recovery and Durability in Immune TTP
An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab.
Abstract
Caplacizumab combined with an abbreviated therapeutic plasma exchange (TPE) course showed no detriment to platelet recovery or durability in immune thrombotic thrombocytopenic purpura (iTTP) patients.